Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Rhea-AI Summary

Dyadic (NASDAQ: DYAI) and Fermbox Bio launched an animal-origin-free Recombinant DNase I (RNase-free) on March 4, 2026, the first commercial product under their expanded collaboration.

The product is available in research grade now; a cGMP-grade version is in development to support biopharma and cell and gene therapy manufacturing. The launch signals Dyadic's move toward commercial product expansion and recurring revenue growth, with more recombinant proteins planned for rollout through 2026 under the partnership.

Positive

• Commercial launch of Recombinant DNase I on March 4, 2026
• First product under expanded Dyadic–Fermbox collaboration, enabling joint commercialization
• cGMP-grade development planned to target biopharma and CGT manufacturing

Negative

• Initial availability is research grade only; cGMP product is still in development
• Commercial revenue impact and timing are not quantified in the announcement

Key Figures

Collaboration expansion year: 2025 Planned product rollout year: 2026

2 metrics

Collaboration expansion year 2025 Expanded Dyadic–Fermbox collaboration announced in 2025

Planned product rollout year 2026 Series of recombinant enzymes and proteins expected throughout 2026

Market Reality Check

Price: $0.8240 Vol: Volume 12,698 is light at...

low vol

$0.8240 Last Close

Volume Volume 12,698 is light at 0.29x the 20-day average of 43,659 shares. low

Technical Shares at 0.7892 are trading below the 0.97 200-day MA and 49.08% under the 52-week high.

Peers on Argus

DYAI was up 3.04% pre-news while momentum peers IGC and RANI were both down arou...

2 Down

DYAI was up 3.04% pre-news while momentum peers IGC and RANI were both down around 3%. Within listed affinity peers, CASI (-38.97%) and LSB (-20.62%) were sharply lower, while PLUR gained 0.86%, indicating mixed sector action and suggesting this announcement is more company-specific than part of a broad biotech move.

Historical Context

5 past events · Latest: Mar 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 02	Commercialization milestone	Positive	-1.7%	Planned 2026 commercialization of non-animal dairy enzyme and milestone payment.
Feb 17	Product launch	Positive	-3.0%	Commercial launch of AlbuFree DX recombinant human albumin with profit-sharing.
Dec 17	Collaboration expansion	Positive	-1.4%	Expanded Fermbox collaboration for commercial-scale animal-free proteins and enzymes.
Dec 15	Commercial partnership	Positive	-9.3%	Partnership with Opes Diagnostics to commercialize recombinant media proteins globally.
Dec 01	Development agreement	Positive	-1.8%	Agreement with BRIG BIO for animal-free bovine alpha-lactalbumin development and revenue share.

Pattern Detected

Recent partnership and commercialization announcements have repeatedly been followed by negative 24h price reactions despite positive business developments.

Recent Company History

Over the last six months, Dyadic has steadily advanced from platform development toward commercial execution. Key steps included a Dec 1, 2025 development and commercialization agreement for animal-free bovine alpha-lactalbumin and multiple partnership launches for recombinant media proteins and growth factors. The Dec 17, 2025 expansion with Fermbox set the framework for today’s DNase I launch. Notably, all five prior positive news items saw 24-hour price declines ranging from about -1% to -9%.

Market Pulse Summary

This announcement marks Dyadic’s first commercial product under its expanded Fermbox collaboration: ...

Analysis

This announcement marks Dyadic’s first commercial product under its expanded Fermbox collaboration: an animal-origin-free recombinant DNase I aimed at research and future cGMP biomanufacturing uses. It builds on a series of late-2025 and early-2026 deals to commercialize animal-free enzymes and media proteins. Investors may track how fast DNase I sales ramp, the timing of additional planned recombinant launches in 2026, and any updates tied to Dyadic’s Nasdaq bid-price compliance deadline of June 17, 2026.

Key Terms

recombinant, cGMP, cell and gene therapy, molecular diagnostics, +2 more

6 terms

recombinant medical

"commercial launch of animal-origin-free Recombinant DNase I (RNase-free)"

Recombinant describes a product made by combining genetic material from different sources so cells can be used as tiny factories to produce a desired protein, vaccine ingredient or enzyme. For investors, the label signals a biotechnology approach that can enable scalable manufacturing, patent protection and targeted therapies, but also brings specific regulatory review, production complexity and clinical risk — similar to a customized recipe that can yield high value but needs precise execution.

cGMP regulatory

"currently available in research grade with a cGMP-grade version in development"

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

cell and gene therapy medical

"support biopharmaceutical manufacturing and cell and gene therapy applications"

Therapies that use living cells or altered genes to treat or cure disease by repairing, replacing or reprogramming parts of the body; think of it as swapping or reprogramming malfunctioning hardware or software inside the body. Investors watch these treatments closely because they can command high prices and offer one-time or long-lasting benefits, but they also carry big development costs, complex manufacturing and regulatory risks that can cause large swings in a company’s value.

molecular diagnostics medical

"sensitive RNA workflows across biological research, biotechnology, and molecular diagnostics"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

cell culture media medical

"targets high-demand segments in cell culture media, media supplementation"

A cell culture media is a liquid 'broth' of nutrients and chemicals used to keep biological cells alive and growing outside the body, similar to potting soil and fertilizer for plants. Investors care because media are an essential, recurring supply for research and drug manufacturing—their quality, availability, and cost affect the pace of development, production efficiency, regulatory compliance and the revenue and margins of suppliers in the biotech supply chain.

precision fermentation technical

"developing sustainable bio-based products through precision fermentation"

Precision fermentation uses edited microbes (like yeast or bacteria) as tiny, programmable factories to produce a single, specific ingredient—such as a protein, enzyme or flavor—rather than making whole foods. Think of it like coding a vending machine to dispense one exact product on demand. For investors, it matters because it can cut production costs, speed up scale-up, reduce reliance on traditional agriculture or chemical synthesis, and create new, high-margin products that can reshape markets and regulatory pathways.

AI-generated analysis. Not financial advice.

JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Fermbox Bio (“Fermbox”), a biotech research and manufacturing company developing sustainable bio-based products through precision fermentation and advanced biotechnology tools, today announced the commercial launch of animal-origin-free Recombinant DNase I (RNase-free). This represents the first commercialized product under the companies expanded collaboration announced in 2025 and marks another step in Dyadic’s accelerating transition from platform development to commercial product expansion and recurring revenue growth.

Produced using Dyadic’s proprietary high-yield fungal microbial expression platforms and Fermbox Bio’s scale-up and biomanufacturing capabilities, Recombinant DNase I (RNase-free) is currently available in research grade with a cGMP-grade version in development to support biopharmaceutical manufacturing and cell and gene therapy applications.

“Launching animal-origin-free Recombinant DNase I marks an important first step in translating our expanded collaboration with Fermbox Bio into commercial products,” said Joe Hazelton, President & COO of Dyadic Applied BioSolutions. “This milestone demonstrates the strength of our microbial expression platforms and our shared ability to bring high-quality, scalable recombinant enzymes and proteins to research and biomanufacturing customers worldwide.”

Recombinant DNase I (RNase-free) is an endonuclease enzyme used for nucleic-acid clean-up and sample preparation workflows where residual DNA can interfere with analytical results. Its RNase-free specification supports RNA integrity in sensitive RNA workflows across biological research, biotechnology, and molecular diagnostics.

DNase I (RNase-free) is a strategically important enzyme and the first in a planned series of recombinant enzymes and proteins expected to be commercially introduced throughout 2026.

Planned pipeline products under the collaboration include recombinant α-lactalbumin, recombinant transferrin, recombinant human FGF-2, recombinant human lactoferrin, and additional recombinant proteins expressed using Dyadic’s fungal microbial platforms. The initial portfolio targets high-demand segments in cell culture media, media supplementation, and molecular biology reagents, supporting applications such as cell and gene therapy (CGT), vaccine and monoclonal antibody manufacturing, regenerative medicine, and advanced biologics development.

Under the collaboration framework, Dyadic provides its fungal microbial expression platforms, production strains, and development support, while Fermbox Bio leads downstream process development, scale-up, and manufacturing. The companies are aligned on global commercialization to serve research and biomanufacturing customers worldwide.

About Dyadic Applied BioSolutions

Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit www.dyadic.com

About Fermbox Bio

Fermbox Bio is a biotechnology research and manufacturing company based in India with a subsidiary in the USA. The company develops sustainable bio-based products using precision fermentation and advanced biotechnology. For more information about Fermbox Bio, please visit www.fermbox.bio

Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of Dyadic’s clinical trial and interest in its protein production platforms, Dyadic’s research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) Dyadic’s history of net losses; (ii) market and regulatory acceptance of Dyadic’s microbial protein production platforms and other technologies; (iii) failure to commercialize Dyadic’s microbial protein production platforms or its other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) Dyadic’s capital needs; (vii) changes in global economic and financial conditions; (viii) Dyadic’s reliance on information technology; (ix) Dyadic’s dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) Dyadic’s ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause Dyadic’s actual results to differ from its current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in Dyadic’s expectations.

Company contacts:

Dyadic Applied BioSolutions:
Joe Hazelton
President & COO
Email: info@dyadic.com

Fermbox Bio:
Mr. Binod Daga
President Business development & Strategic Partnerships
Email: Info@fermbox.bio

FAQ

What did Dyadic announce about Recombinant DNase I (RNase-free) on March 4, 2026 (DYAI)?

Dyadic announced the commercial launch of an animal-origin-free Recombinant DNase I, available in research grade now. According to the company, a cGMP-grade version is in development to support biopharmaceutical and cell and gene therapy manufacturing applications.

How does the Dyadic–Fermbox collaboration affect DYAI's product pipeline in 2026?

The collaboration will commercialize recombinant enzymes and proteins throughout 2026, starting with DNase I. According to the company, planned pipeline products include recombinant α-lactalbumin, transferrin, FGF-2, and lactoferrin.

Is the Recombinant DNase I (RNase-free) from DYAI cGMP-certified for biomanufacturing?

No, the product is currently offered in research grade; a cGMP-grade version is being developed. According to the company, cGMP development aims to support biopharmaceutical manufacturing and CGT applications.

What roles do Dyadic and Fermbox play under their expanded collaboration (DYAI)?

Dyadic provides fungal microbial expression platforms and production strains; Fermbox leads downstream development and scale-up. According to the company, both partners are aligned on global commercialization to serve research and biomanufacturing customers.

What market applications does Dyadic expect for the new Recombinant DNase I (RNase-free)?

The enzyme targets nucleic-acid clean-up in research, biotechnology, molecular diagnostics, cell culture media, and CGT workflows. According to the company, its RNase-free specification supports RNA integrity in sensitive RNA workflows.